UnitedHealth under criminal probe for possible Medicare fraud, WSJ reports
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment deteriorates further in October
- CoreWeave stock drops on dilution fears and debt concerns
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
- Anthropic launches cyber defense program for infrastructure and open-source
Raymond James Cuts Estimates on UnitedHealth Group (UNH), 'Needless to say we think these earnings are low-quality and non-recurring in nature'
May 16, 2025 5:03 AM EDTRaymond James analyst John Ransom reiterated a Market Perform rating and {REMOVEPT} price target on UnitedHealth Group (NYSE: UNH)
The analyst comments "We are reiterating our Market Perform rating on UNH and taking a sharper pencil to our numbers as we are cutting our 2025 adj. EPS estimate to $20/share (down from $22), and our 2026 EPS estimate to $23/share (down from $25). In our analysis we rebased the 2024 EPS down to $23.97 to account for $4.0B ($3.70 of EPS) of one-time accounting gains that UNH booked as earnings in 2024. After combing through the 10-K, the $4B was... More
UnitedHealth Group (UNH) PT Lowered to $405 at JPMorgan, Stays Overweight, ' some of the uncertainty around cost trend should subside.'
May 15, 2025 3:45 AM EDTJPMorgan analyst Lisa Gill lowered the price target on UnitedHealth Group (NYSE: UNH) to $405.00 (from $525.00) while maintaining a Overweight rating.
The analyst comments "
Following UNH leadership change and suspension of 2025 guidance (see our takeaways here), we are updating our estimates. For a discussion of recent events and our estimate changes, see slides attached. Our 2025 adj. EPS estimate of $22.26 reflects an estimated MLR of 88.6% given the elevated care activity that has worsened in the last month. Looking to 2026e, we assume ~10% y/y adj. EPS growth ($24.58), as we look for progress towards mitigating... More



